Work

Recalcitrant Issues and New Frontiers in Nano-Pharmacology

Year: 2019

Type: article

Abstract: Packaging of old pharma drugs into new packaging “nanoparticles” is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil® in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only ~20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.

Source: Frontiers in Pharmacology

DOI: 10.3389/fphar.2019.01369

Authors: Vinay Bhardwaj, Ajeet Kaushik, Ziad M. Khatib, Madhavan Nair, Anthony J. McGoron

Institutions: The College of New Jersey, Florida Polytechnic University, Miami Children's Hospital, Florida International University

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,950